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Background: Type-2 diabetes is associated with systemic inflammation and higher C-reactive protein (CRP) levels.
However, the longitudinal association of CRP and haemoglobin-A1c (HbA1c) has not been described in large prospective
studies. Understanding such associations may shed light on the role of inflammation in development of type-2 diabetes
and its complications such as cardiovascular diseases.
Methods: EPIC-Norfolk is a cohort study of men and women aged 40–79 years at time of recruitment (1993–1997).
Serum CRP (mg/l) was measured using a high-sensitivity assay at baseline and 13-years follow-up. HbA1c (%) was
measured at baseline, 4, and 13 years. Participants were excluded if they were diagnosed with diabetes or were
taking diabetes medication. Data on at least one measurement of CRP and HbA1c was available for 14228 participants
(55 % of the cohort).
Results: In the cross-sectional analysis of baseline data, a 1-SD higher loge-CRP (about three-fold higher CRP) was associated
with 0.06 (95 % CI 0.04, 0.08) higher HbA1c (%) adjusted for potential confounders. In longitudinal analysis using multivariable
linear mixed models, change in CRP over 13 years was to a similar extent positively associated with increase in HbA1c,
such that 1-SD higher longitudinal change in loge-CRP was associated with 0.04 (95 % CI 0.02, 0.05) increase in HbA1c.
Conclusion: In this study we found longitudinal observational evidence suggesting that increase in systemic inflammation
is associated with an increase in HbA1c and thus systemic inflammation may have a role in development of type-2
diabetes and its complications.
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Serum C-reactive protein (CRP) is a marker of systemic
inflammation and has been shown to be associated with
incident type 2 diabetes [1,2]. Patients with type 2 dia-
betes are also at risk of developing micro-vascular and
macro-vascular complications such as diabetic retinop-
athy, nephropathy, neuropathy, atherosclerosis, and car-
diovascular diseases. The potential etiologic role of
chronic systemic inflammation in the pathogenesis of type* Correspondence: s.ahmadi-abhari@ucl.ac.uk
1Department of Public Health and Primary Care, University of Cambridge,
Cambridge, UK
3Department of Public Health and Primary Care, University of Cambridge,
Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
Full list of author information is available at the end of the article
© 2015 Ahmadi-Abhari; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.2 diabetes and in the link between diabetes and micro-and
macro-vascular complications is not well known.
Haemoglobin A1c (HbA1c) concentrations in patients
with diabetes are associated with risk of developing
micro- and macro-vascular complications, and is thus
used as the “gold standard” for monitoring glucose con-
trol in patients with type 2 diabetes [3]. HbA1c has also
been advocated to be used as a marker for diagnosis of
type 2 diabetes [3]. Therefore, understanding the associ-
ation between markers of systemic inflammation (such as
CRP) and haemoglobin A1c may help better understand the
potential role of inflammation in the development of type 2
diabetes and in the mechanisms involved in development
of complications in patients with diabetes. A positiveral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been reported previously [4-7]. However, the temporal as-
sociation of CRP and HbA1c over time has not been de-
scribed. Exploring the longitudinal association between
changes in CRP and changes in HbA1c over time in large-
scale observational studies should be more informative of
the nature of any temporal associations than in cross-
sectional studies. In this study we aimed to examine the
longitudinal association of CRP and HbA1c in a large pro-
spective cohort study with repeated measurements of
CRP, HbA1c, and other confounders, over 13 years of fol-
low up.
Methods
Study participants were recruited in the European Pro-
spective Investigation into Cancer in Norfolk (EPIC-
Norfolk) study. Details of this study have been previ-
ously described [8]. Briefly, 25,639 men and women,
aged 40–79, resident in Norfolk, England were recruited
to the study using general practice age and sex registers.
The age-sex structure of the participants recruited in the
study was approximately similar to the UK population age-
sex structure according to registers in the United Kingdom.
Study participants attended the baseline health examin-
ation between 1993 and 1997, a second health examination
at around 4 years, and a third health examination around
13 years after recruitment. The EPIC-Norfolk study was
approved by the Norfolk Local Research Ethics Committee,
and all volunteers gave written informed consent.
At the clinic visits, extensive demographic, medical,
lifestyle, family history and dietary data were collected
by asking participants to complete a health and lifestyle
questionnaire. Smoking status was categorized into
current-, former-, and never-smokers, and alcohol con-
sumption was computed as units per week. Medication
use (including use of corticosteroids and postmeno-
pausal hormone replacement therapy (HRT)) was
assessed by self-report on the health and lifestyle ques-
tionnaire and by examining medications brought by the
participants to the clinic visit. Habitual physical activity
was assessed using the EPIC-validated short physical ac-
tivity questionnaire by combining levels of occupational
and leisure-time physical activity into 4 categories [9].
Participants were excluded from the present analysis if
they were diagnosed with diabetes by a physician at
baseline, or were taking diabetes medication. Prevalent
and incident cases of type-2 diabetes were either ascer-
tained by self-report of diabetes diagnosed by a phys-
ician, as well as by self-report of new administration of
diabetes medication at follow up provided that it was
verified by medical records, or by record linkage with
external sources independent of individuals’ participa-
tion in follow up health examinations or postal question-
naires. External sources used to ascertain diabetes casesinclude listing with general practice diabetes registers,
local hospital outpatient diabetes registers, hospital ad-
missions information that screened for diabetes related
conditions, and Office for National Statistics mortality
data with coding for diabetes.
At the clinic visits, trained nurses took anthropometric
measurements on individuals in light clothing without
shoes. Height was measured to the nearest millimetre using
a free standing stadiometer and weight was measured to the
nearest 100 g using digital scales. Body mass index (BMI)
was calculated as weight in kilograms divided by the square
of height in metres. Waist circumference was measured to
the nearest millimetre using a D-loop tape measure.
HbA1c (%) was measured in fresh EDTA blood sam-
ples by using high-performance liquid chromatography
at baseline and second health examination using the
BioRad Diamat Automated Glycosylated Haemoglobin
Analyser (Hemel Hempstead, United Kingdom), and at
the third health examination using the Tosoh Auto-
mated Glycohemoglobin Analyzer.
Blood samples used for measurement of CRP at baseline
were centrifuged at 2,100 g for 15 min at 4 °C and then
kept frozen in −80 °C freezers until being thawed in 2008
for assaying CRP. Serum high-sensitivity CRP (mg/l) was
measured using the Olympus AU640 chemistry analyzer
(Olympus Diagnostics, United Kingdom). CRP was not
measured at the second health examination, but was mea-
sured at the third health examination in fresh blood sam-
ples using the Siemens Dimension clinical chemistry
analyzer (Siemens Dimension clinical chemistry analyzer,
Newark, Delaware, US).
Statistical analysis
Serum CRP and HbA1c levels were analysed as continuous
and categorical variables in separate analyses. Serum CRP
had a right skewed distribution and for continuous ana-
lysis was log-transformed to obtain a normal distribution.
For categorical analyses CRP was divided into 4 clinically
relevant categories using cut-points 1, 3, and 10 mg/l.
In cross-sectional analysis using baseline data, multiple
linear regression analysis was used to examine mean dif-
ference in HbA1c across CRP categories. Analyses were
adjusted for age, sex, BMI, waist circumference, smok-
ing, physical activity, alcohol intake, corticosteroid medi-
cation, and for women only, menopausal status and
HRT use. Missing values for categorical variables were
coded as such and thus individuals with missing data
were not excluded from the analyses.
In longitudinal analyses, linear mixed models were
used to examine the rate of change of HbA1c across
baseline CRP categories. The rate of change of HbA1c
across categories of CRP was modelled as a fixed-effect
interaction between follow up time (years) and CRP cat-
egories, allowing for subject-specific random effects for
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differences in longitudinal rates of change in HbA1c levels
by baseline CRP levels was assessed based on P-value for
continuous interaction between baseline loge-CRP and
time, with subject-specific random effects for the intercept
and time. The magnitude of longitudinal change in HbA1c
associated with a standard deviation (SD) longitudinal in-
crease in loge-CRP (corresponding to a three-fold increase
in original CRP (mg/l) values) over time was calculated by
fitting a linear mixed model allowing for random subject
specific slopes for loge-CRP and random subject specific
intercepts. All covariates were treated as time-varying in
the longitudinal analysis to account for changes in life-
style and anthropometric factors over time.
Linear mixed models treat missing data as “missing at
random”. However, loss to follow-up in our study was likely
to be due to higher morbidity and mortality (N = 1,074
(14 %) of participants included in the analysis at baseline
died during follow-up), both of which are associated with
CRP and HbA1c measures. Therefore, to minimize selection
bias, we performed a complete case analysis in which we
restricted the longitudinal analyses to participants that hadTable 1 Baseline characteristics of European Prospective Investigatio
C-reactive protein and in total recruited in 1993–1997*
All participants
n = 14,228
Age 58.0 (9.0)
Haemoglobin A1c (%)** 5.3 (0.7)
Body mass index (Kg/m2) 26.1 (3.7)
Waist Circumference (cm) 87.3 (12.1)
Alcohol (units/week) 7.1 (9.1)
Sex (% male) 6,211 (43.7 %)
Smoking Current 1,488 (10.5 %)
Former 5,825 (41.3 %)
Never 6,809 (48.2 %)
Physical activity Inactive 3,958 (27.8 %)
Moderately inactive 4,104 (28.8 %)
Moderately active 3,370 (23.7 %)
Active 2,796 (19.7 %)
Prevalent disease Cancer 733 (5.2 %)
Myocardial Infarction 392 (2.8 %)
Stroke 166 (1.2 %)
Corticosteroid medication use 408 (2.9 %)
Postmenopause 6,129 (76.5 %)
Hormone replacement therapy (% current use) 1,751 (21.9 %)
*Values are mean (standard deviation) or number (%)
**Baseline characteristics are presented for all participants who had C-reactive protein da
longitudinal analyses conducted in this study. The mean (SD) of Haemoglobin A1c presen
measurement at baseline. All other baseline characteristics are presented for a total of
health examinationadequate data for analysis at baseline and at least one
follow-up health examination. The analyses were also re-
peated stratified by sex and BMI. Since the associations
were similar in sex stratified analyses, all subsequent results
are presented as sex-combined. All analyses were per-
formed using Stata 12.0 (StataCorp. College Station, TX).
Results
A total of 14,228 participants who were free of diabetes
(as ascertained from self-report or medical records), had
data on CRP at baseline, and at least one measurement of
HbA1c, were included in the present analysis. The mean
age of participants at baseline was 58 years (SD = 9) and
44 % were male (Table 1). The mean (SD) duration of fol-
low up was 3.7 (0.7) and 13.1 (1.8) years at the second and
third examinations respectively. Among participants that
attended the baseline and follow-up health examinations,
median (inter-quartile range) CRP (mg/l) at baseline and
13 years was 1.4 (0.7-3.0) and 2.0 (1.3-3.4) respectively.
Mean (standard deviation (SD)) HbA1c (%) at baseline, 4,
and 13 years were 5.3 (0.7), 5.5 (0.5), and 5.8 (0.6)
respectively.n into Cancer -Norfolk cohort participants by categories of
C-reactive protein (mg/L)
≤1 1.1-3 3.1-10 >10
n = 5,460 n = 5,249 n = 2,927 n = 592
55.7 (8.8) 59.0 (8.8) 60.1 (8.8) 60.7 (8.6)
5.1 (0.6) 5.3 (0.6) 5.4 (0.7) 5.6 (0.9)
24.7 (3.0) 26.5 (3.4) 27.8 (4.2) 27.5 (4.8)
83.6 (11.2) 88.5 (11.6) 91.5 (12.2) 91.5 (13.0)
7.2 (8.7) 7.2 (9.5) 6.7 (9.5) 6.5 (8.6)
2,412 (44.2 %) 2,361 (45.0 %) 1,177 (40.2 %) 261 (44.1 %)
445 (8.2 %) 530 (10.2 %) 413 (14.3 %) 100 (17.0 %)
2,060 (37.9 %) 2,262 (43.4 %) 1,249 (43.1 %) 254 (43.3 %)
2,926 (53.9 %) 2,415 (46.4 %) 1,235 (42.6 %) 233 (39.7 %)
1,196 (21.9 %) 1,523 (29.0 %) 1,016 (34.7 %) 223 (37.7 %)
1,582 (29.0 %) 1,525 (29.1 %) 825 (28.2 %) 172 (29.1 %)
1,433 (26.3 %) 1,214 (23.1 %) 608 (20.8 %) 115 (19.4 %)
1,249 (22.9 %) 987 (18.8 %) 478 (16.3 %) 82 (13.9 %)
239 (4.4 %) 287 (5.5 %) 171 (5.8 %) 36 (6.1 %)
87 (1.6 %) 162 (3.1 %) 107 (3.7 %) 36 (6.1 %)
41 (0.8 %) 65 (1.2 %) 48 (1.6 %) 12 (2.0 %)
103 (1.9 %) 147 (2.8 %) 121 (4.1 %) 37 (6.3 %)
2,024 (66.4 %) 2,324 (80.5 %) 1,505 (86.1 %) 276 (83.4 %)
435 (14.3 %) 658 (22.8 %) 542 (31.0 %) 116 (35.1 %)
ta at baseline health examination and were included in either the cross-sectional or
ted in this table is based on a total of 7,485 participants who had Haemoglobin A1c
14,228 participants who had Haemoglobin A1c measured at a minimum of one
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CRP levels tended to be older, had higher HbA1c levels,
waist circumference, and BMI, were less likely to be
physically active, more likely to smoke, have a pre-
existing history of disease, and more likely to take cor-
ticosteroid medication or HRT (Table 1).
In cross-sectional multiple linear regression analyses
(Table 2), a 1-SD higher baseline loge-CRP (about three-
fold higher CRP on the original scale (mg/L)) was associ-
ated with 0.09 (95 % CI 0.07, 0.10) higher HbA1c (%) ad-
justed for age and sex. The corresponding value was
0.06 (95 % CI 0.04, 0.08) after adjustment for other co-
variates. Multivariable adjusted mean HbA1c levels were
higher in participants with higher baseline CRP levels
(Fig. 1). No significant interaction by sex or BMI was ob-
served and the positive associations persisted in strati-
fied analyses (Fig. 1).
HbA1c increased by about 0.05 (SD = 0.05) annually. In
longitudinal analyses, the annualised rates of change of
HbA1c was significantly associated with baseline CRP
levels adjusted for age, sex and follow-up time (P = 0.02
for continuous baseline loge CRP*time interaction,
Table 2). Annualized rates of change of HbA1c were no
longer significantly associated with baseline CRP levels
in multivariable analysis. The results were not changed
when analysis was restricted to individuals who had data
for CRP, HbA1c, and other covariates at baseline and
third health examination (data not shown).
In addition to baseline levels of CRP, change in CRP
over time was also significantly and positively associated
with longitudinal change in HbA1c (Fig. 2). A 1-SD incre-
ment in loge CRP (corresponding to 3-fold increase inTable 2 Cross-sectional and longitudinal association of Haemoglobin
cohort study (1993–2011)
Cross-sectional associationa
n = 7,485
CRP levels (mg/L) Age-sex adjusted Multivariable
Mean difference (95 %
confidence interval)
Mean differen
confidence in
≤1 Reference Reference
1.1 – 3 0.065 (0.032, 0.098) 0.040 (0.007,
3.1 – 10 0.198 (0.159, 0.238) 0.143 (0.101,
>10 0.308 (0.236, 0.379) 0.256 (0.183,
1-SD increase in CRP 0.086 (0.071, 0.10) 0.059 (0.046,
P-value <0.001 <0.001
CRP C-reactive protein, EPIC-Norfolk European Prospective Investigation into Cancer
aMean difference in HbA1c (%) in each category of CRP and the reference category
covariates: age, sex, body mass index, waist circumference, smoking, physical activi
corticosteroid medication, and in women only menopausal status and hormone rep
bAnnual change calculated as an interaction of baseline CRP categories with time in
baseline age and sex. Multivariable analyses are additionally adjusted for body mas
history of cancer, myocardial infarction, and stroke, corticosteroid medication, and in w
time varying variables. Analysis is restricted to individuals who had at least two measu
cValues are change in HbA1c over 13 yearsCRP on the original mg/l scale) over 13 years of follow-up
was associated with an increase of 0.06 (95 % CI 0.04,
0.07) in HbA1c adjusted for age, sex, and follow up time.
After adjustment for changes in other covariates in multi-
variable models, the associations attenuated but remained
statistically significant, such that a three-fold increase in
CRP over 13 years was associated with 0.04 (95 % CI 0.02,
0.05) increase in HbA1c over the same period.
Discussion
In this study we found a cross-sectional positive associ-
ation between serum CRP and HbA1c. A 1-SD higher
loge-CRP was cross-sectionally associated with approxi-
mately 0.06 higher HbA1c (%). Changes in levels of serum
CRP over time were also positively associated with change
in HbA1c levels, but to a lesser extent to that found in
cross-sectional analysis; such that 1-SD increase in loge-
CRP levels over time was associated with ~ 0.04 increase
in HbA1c (%) over the same period. These associations
were largely independent of age, sex, BMI, waist circum-
ference, smoking status, physical activity, alcohol intake,
medical history of diseases, corticosteroid medication,
and HRT use.
The cross-sectional positive association between CRP
and HbA1c levels has been previously shown in studies in-
volving participants with diabetes [5] and without diabetes
[4, 6, 7] among different populations and age groups. The
multivariable adjusted cross-sectional associations of
HbA1c and log-CRP observed in the present analysis were
similar to those in previous studies [4, 6, 7]. CRP has also
been shown to be positively associated with incident type
2 diabetes in previous studies [1, 2]. However, to the bestA1c with baseline levels of C-reactive protein in the EPIC-Norfolk
Longitudinal associationb
n = 4,595
adjusted Age-sex adjusted Multivariable adjusted
ce (95 %
terval)
Annual change (95 %
confidence interval)
Annual change (95 %
confidence interval)
0.043 (0.041, 0.045) 0.039 (0.031, 0.046)
0.074) 0.045 (0.043, 0.047) 0.040 (0.032, 0.047)
0.185) 0.048 (0.044, 0.051) 0.040 (0.031, 0.047)
0.328) 0.052 (0.045, 0.059) 0.041 (0.028, 0.054)
0.072) 0.003 (0.0002, 0.005)c 0.002 (−0.0007, 0.004)c
0.02 0.15
in Norfolk, SD standard deviation
(CRP ≤ 1 mg/l). Multivariable cross-sectional analyses are adjusted for baseline
ty, alcohol intake, medical history of cancer, myocardial infarction, and stroke,
lacement therapy
participants who had at least one follow-up health examination. Adjusted for
s index, waist circumference, smoking, physical activity, alcohol intake, medical
omen only menopausal status and hormone replacement therapy, all treated as
rements of HbA1c
Fig. 1 Mean haemoglobin A1c (HbA1c) by C-reactive protein (CRP) categories measured at baseline health examination of the EPIC-Norfolk cohort
study (1993–1997), among a) all participants and stratified by b) sex, and c) body mass index. Grey bars are mean HbA1c (%) levels adjusted for age and
sex. Black bars are additionally adjusted for body mass index waist circumference, smoking, physical activity, alcohol intake, medical history of cancer,
myocardial infarction, and stroke, corticosteroid medication, and in women only menopausal status and hormone replacement therapy. Normal weight
refers to BMI below 25, over weight refers to BMI of 25 to 30, and obese refers to BMI over and equal to 30
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CRP and HbA1c has not been previously reported.
Strengths and limitations
An important consideration in investigating the role of in-
flammation in development of diabetes and abnormal glu-
cose metabolism is confounding by obesity. Obesity and
high body fat are associated with diabetes and abnormal
glucose metabolism, as well as with elevated circulating
levels of CRP and other pro-inflammatory cytokines
[10-12]. A strength of the present study is the large sample
size and the availability of repeated measurements of all
variables including BMI and waist circumference. Avail-
ability of repeated measurements reduces the possibility of
measurement error and also enables us to better account
for concurrent changes in confounding factors (such as
BMI and waist circumference) over time and thusenabling better understanding of the association between
inflammation and glucose metabolism independent of
obesity.
We excluded participants who were diagnosed with dia-
betes by a physician or were taking diabetes medication at
baseline because treatment for diabetes might affect the
association between CRP and HbA1c. We also restricted
the analyses to individuals who attended both the baseline
and follow up health examinations, and had adequate data
required for analysis, to avoid potential bias due to lower
survival in those with higher CRP and HbA1c levels.
A limitation of the present study was that CRP at base-
line was measured in serum samples that were kept frozen
for about 15 years [13]. However, previous studies have
shown that CRP is relatively stable in frozen plasma [14].
CRP at the third health examination was measured in
fresh serum samples using a different chemistry analyzer.
Fig. 2 Association between the mean annual change in haemoglobin A1c (HbA1c) and the mean annual change in C-reactive protein (CRP)
measured at baseline and third health examinations in the EPIC-Norfolk cohort study (1993–2011), adjusted for baseline age and sex.
*Change in log-CRP is equivalent to percentage change in CRP on the original mg/l scale. For example 0.1 units change in log-CRP is
roughly equivalent to 10 % change in CRP (mg/l) values
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ment of CRP and HbA1c across different time points may
have increased the measurement error. However, the intra-
class correlation coefficient between measurements of
HbA1c (0.62) was considerably higher than that of systolic
blood pressure (0.39) and LDL-cholesterol (0.28), and the
intra-class correlation coefficient between the two mea-
surements of log CRP (0.39) was similar to that of systolic
blood pressure, and higher than that of LDL cholesterol
measured at the same time points in the EPIC-Norfolk
study (unpublished data). Similar results were reported in
other studies [10, 15].Biological mechanisms
Although we observed a temporal positive association
between change in CRP and change in HbA1c, it is not
possible from an observational study to infer causality.
Knowledge of biological mechanisms justifies the plausi-
bility of association. Tumour necrosis factor alpha
(TNF-α), and interleukin-6 (IL-6) are pro-inflammatory
cytokines over expressed in adipose tissue. IL-6 and
TNF-α in turn stimulate hepatic production of CRP
[16]. The link between obesity inflammation, and abnor-
mal glucose metabolism may in part be related to in-
creased production of pro-inflammatory cytokines such as
IL-6 and TNF-α in adipose tissue. TNF-α is suggested to
induce insulin resistance [17]. Interleukin-6 and CRP are
also shown in animal studies to impair insulin signalling
and insulin sensitivity mainly through insulin receptor
substrate phosphorylation [18-22]. Further investigation of
the association between CRP and markers of insulinresistance such as HOMA-IR is required to underpin this
hypothesis.
Higher levels of CRP and leptin were shown to be asso-
ciated with increased metabolic syndrome components
[23]. On the other hand, plasma leptin levels are associ-
ated with vascular endothelial function in overweight pa-
tients with type 2 diabetes [24] and leptin was found to be
directly related to CRP independently of BMI and other
confounding factors especially in men [25]. These findings
are consistent with and support a role of CRP and inflam-
mation in abnormal glucose metabolism.
CRP is a marker of an age-related pro-inflammatory
process described as “inflamm-aging” [26-28]. According
to this theory, long-term exposure to a variety of antigens
(infection, food, etc.) results in progressive filling of the
immune system by activated immune cells and pro-
inflammatory cytokines. This process may lead to a re-
duced capacity to respond to infectious and stress factors
later in life. It may additionally lead to a pro-inflammatory
state resulting from increased activated immune cells and
pro-inflammatory cytokines. The pro-inflammatory state
is suggested to cause long-term tissue damage and an in-
creased susceptibility to non-infectious diseases, such as
diabetes and impairments in glucose metabolism, where
immunity and inflammation play a role [26-29]. The stud-
ies exploring the association between CRP related genes
and HbA1c levels or incident diabetes do not support a
causal role for CRP [30]. Nevertheless, CRP genotype
polymorphisms are associated with a small difference
(about 60 %) in serum CRP levels, and of insufficient mag-
nitude for an association with incident diabetes to be de-
tected. Moreover, the negative findings of the studies
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clude a causal role for the inflammatory process (of which
CRP is an indicator) in development of diabetes.
It remains unclear whether systemic inflammation has a
causal role in development of diabetes and related condi-
tions, or whether it is a case of reverse causation, i.e., dis-
turbance in glucose metabolism being accountable for
causing systemic inflammation. Previous studies have
shown that hyperglycaemia induces secretion of pro-
inflammatory cytokines and acute phase reactants by adi-
pocytes and monocytes [31,32]. Moreover, the possibility
of the temporal association between CRP and HbA1c be-
ing due to residual confounding by unmeasured genetic,
lifestyle, or environmental factors cannot be ruled out.
Conclusions
The associations observed in the present study provide
observational evidence suggesting that systemic inflamma-
tion may potentially have an etiologic role in development
of diabetes and may be involved in the link between ele-
vated HbA1c levels and development of diabetic complica-
tions such as cardiovascular diseases. Further biological
and interventional studies are required to elucidate these
hypotheses.
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